InvestorsHub Logo

JNdouble1

09/26/22 11:24 AM

#299532 RE: Threepointer #299530

"Sorry, high risk fda play"

I think the point is understood, but this is no longer an FDA play.

Sure, there is room for even more indications that need approval. And there is always room for new versions of the device that require subsequent clearance from the agency.

Since we have all the approvals we need to either succeed or fail in the markets worldwide, this is now more of a do or die will it sell play. Of course being a pink sheet OTC stock, there are opportunities for trades against news. The upcoming Synergy news will brink a big price increase I hear.

Steve43

09/26/22 11:31 AM

#299534 RE: Threepointer #299530

They are desperate to have a revenue steam, who Biel or the OEM, The OEM’s are already successful companies with revenue streams. As I said KT having an FDA approved product with.their name on it , is akin to hitting the Jackpot. Plus they keep us out of the U.S. Market with Actipatch. This is all in the public view. We brought them on to take over the Advertising and Marketing costs, problem is they are not spending any money doing either. JMHO